

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Ryozo NAGAI et al.

Group Art Unit : 1611

Appl. No. : 10/598,275

Examiner : Kyle Purdy

I. A. Filed : February 24, 2005

Confirmation No. : 2170

For : MEDICINE CAPABLE OF INHIBITING ACTIVATION OF
TRANSCRIPTION FACTOR KLF5

**SUBMISSION UNDER 37 C.F.R. 1.114
IN RESPONSE TO FINAL OFFICE ACTION DATED JUNE 16, 2009**

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, **Mail Stop AF**
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

This Submission is in response to the Final Office Action dated September 2, 2010 to which an Amendment Under 37 C.F.R. 1.116 was filed January 18, 2011, an Advisory Action was mailed February 2, 2011, a Notice of Appeal was filed February 25, 2011, an Appeal Brief was filed April 22, 2011, and an Examiner's Answer was mailed September 12, 2011 vacating an Examiner's Answer mailed July 12, 2011.

Applicant is filing on even date herewith a Request for Continued Examination with this paper being part of the Submission of the Request for Continued Examination.

An extension of time should not be necessary for maintaining the pendency of the application. However, if for any reason any extension of time is required to maintain the pendency of the application, the present submission should be interpreted to include the requisite Request for Extension of Time, and the Patent and Trademark Office is hereby authorized to

charge any fee necessary to preserve the pendency of this application, including any required extension of time fee and/or any required claim fee, to Deposit Account No. 19-0089.

Remarks begin on 3 of this paper.

Entry of this reply and reconsideration and withdrawal of the rejections of record are respectfully requested.